NASDAQ:COCP Cocrystal Pharma (COCP) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free COCP Stock Alerts $1.73 -0.02 (-1.14%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.70▼$1.9650-Day Range$1.40▼$1.7552-Week Range$1.33▼$3.29Volume47,224 shsAverage Volume15,519 shsMarket Capitalization$17.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Cocrystal Pharma alerts: Email Address Cocrystal Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside478.3% Upside$10.00 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.30) to ($1.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector472nd out of 925 stocksPharmaceutical Preparations Industry215th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Cocrystal Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.11% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cocrystal Pharma has recently increased by 433.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COCP. Previous Next 2.7 News and Social Media Coverage News SentimentCocrystal Pharma has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.06% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.72% of the stock of Cocrystal Pharma is held by institutions.Read more about Cocrystal Pharma's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cocrystal Pharma are expected to grow in the coming year, from ($2.30) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cocrystal Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Cocrystal Pharma Stock (NASDAQ:COCP)Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Read More COCP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COCP Stock News HeadlinesMay 1, 2024 | finance.yahoo.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaMay 1, 2024 | globenewswire.comEnrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 23, 2024 | finance.yahoo.comCOCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…April 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)March 28, 2024 | msn.comCOCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023March 28, 2024 | finanznachrichten.deCocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 28, 2024 | benzinga.comRecap: Cocrystal Pharma Q4 EarningsMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 28, 2024 | globenewswire.comCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 20, 2024 | finanznachrichten.deCocrystal Pharma, Inc.: Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AMarch 19, 2024 | markets.businessinsider.comCocrystal Pharma Receives Pre-IND Feedback Regarding CC-42344 - Quick FactsMarch 19, 2024 | globenewswire.comCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AFebruary 24, 2024 | investing.comCocrystal Pharma Inc (COCP)February 20, 2024 | finance.yahoo.comCOCP: Cocrystal Pharma provides updates on its clinical programs.February 11, 2024 | morningstar.comCocrystal Pharma Inc COCPJanuary 4, 2024 | finance.yahoo.comCocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesDecember 26, 2023 | benzinga.comCocrystal Pharma Stock (NASDAQ:COCP), Analyst Ratings, Price Targets, PredictionsDecember 26, 2023 | benzinga.comCocrystal Pharma Stock (NASDAQ:COCP) Dividends: History, Yield and DatesDecember 6, 2023 | finance.yahoo.comCocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANovember 29, 2023 | finance.yahoo.comCocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNovember 27, 2023 | finance.yahoo.comCocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023November 14, 2023 | benzinga.comCocrystal Pharma Stock (NASDAQ:COCP) Earnings Dates and Earning CallsNovember 14, 2023 | msn.comCOCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.November 13, 2023 | benzinga.comRecap: Cocrystal Pharma Q3 EarningsNovember 13, 2023 | finance.yahoo.comCocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNovember 9, 2023 | finance.yahoo.comCocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastSee More Headlines Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/11/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COCP CUSIPN/A CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+478.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.62% Return on Assets-54.62% Debt Debt-to-Equity RatioN/A Current Ratio8.92 Quick Ratio8.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book0.67Miscellaneous Outstanding Shares10,174,000Free Float7,624,000Market Cap$17.59 million OptionableNot Optionable Beta1.30 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Roger D. Kornberg Ph.D. (Age 77)Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board Comp: $130kDr. Sam Lee Ph.D. (Age 64)Co-Founder, Co-CEO & President Comp: $559.82kKey CompetitorsTonix PharmaceuticalsNASDAQ:TNXPVaxxinityNASDAQ:VAXXTraws PharmaNASDAQ:TRAWTalpheraNASDAQ:TLPHAytu BioPharmaNASDAQ:AYTUView All Competitors COCP Stock Analysis - Frequently Asked Questions Should I buy or sell Cocrystal Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares. View COCP analyst ratings or view top-rated stocks. What is Cocrystal Pharma's stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 478.3% from the stock's current price. View analysts price targets for COCP or view top-rated stocks among Wall Street analysts. How have COCP shares performed in 2024? Cocrystal Pharma's stock was trading at $1.7222 at the beginning of the year. Since then, COCP shares have increased by 0.4% and is now trading at $1.7292. View the best growth stocks for 2024 here. When is Cocrystal Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our COCP earnings forecast. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.13. When did Cocrystal Pharma's stock split? Cocrystal Pharma shares reverse split before market open on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI). How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COCP) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlace[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
